ASCO® 2025 Highlights: Presenter Vignette – Sarah Lochrin
Sarah Lochrin
MB, BCh
Memorial Sloan Kettering Cancer Center
9513
Single dose of neoadjuvant ipilimumab and nivolumab in resectable melanoma with CD8+ cell imaging: Interim results of the C-IT Neo trial.
Interested in learning more about these abstracts and other trials presented at ASCO® 2025? Be sure to register for one of our licensed Best of ASCO® events in a city near you.
This program has been made possible through unrestricted support from Boehringer Ingelheim, Eli Lilly and Ipsen
